Jayex Technology Limited Overview
| Item | Detail | Source |
|---|---|---|
| Current legal name (listed entity) | Jayex Technology Limited | FY2021 Appendix 4E; ASX |
| Former name | Jayex Healthcare Limited (until 31 May 2021) | Market Index former names register |
| ABN | 15 119 122 477 | 1H FY2022 Appendix 4D |
| Holding company incorporation | 2006, Australia (the ACN 119 122 477 series indicates a 2006 registration; MarketBeat gives "founded 2006") | MarketBeat; ABN |
| Operating brand founded | 1978 (Jayex, UK LED information displays) | jayex.com "About"; CB Insights |
| Incorporation jurisdiction | Australia (Corporations Act 2001) | 1H FY2022 Appendix 4D, Note 1 |
| Registered office / principal place of business (latest disclosed) | Level 4, 100 Albert Road, South Melbourne, VIC 3205 | 1H FY2022 Appendix 4D, Note 1 |
| Earlier head office | 17B Cribb Street, Milton, QLD | CB Insights; MarketBeat |
| Exchange / ticker | ASX: JTL (formerly JHL); suspended | Market Index |
| ASX listing date | 17 December 2015 | Market Index corporate details |
| ISIN / CUSIP | ASX ISINs follow the AU0000000XXX format, but the specific code was not confirmed for this dossier. No CUSIP (no US listing). | — |
| Fiscal year end | 31 December | Appendix 4E FY2021 |
| Employees (latest) | Not publicly disclosed. Proxy: employee benefits expense A$3.15m (FY2020) and A$3.05m (FY2021). | FY2021 Appendix 4E |
| Auditor | William Buck Audit (VIC) Pty Ltd | 1H FY2022 review report; Market Index |
| Share registry | Automic Group | Market Index |
| Shares on issue | 281.28 million (31 Dec 2022 and 31 Dec 2023) | Morningstar via Market Index |
| Market capitalisation (current) | About A$0.28m at the last trade of A$0.001; non-tradeable while suspended | Simply Wall St (A$281.3k); Market Index |
| Market capitalisation, 31 Dec 2023 | A$2.53m (EV A$6.06m) | Morningstar via Market Index |
| Website (listed entity, historical) | jayex.com/en-au/ and jayex.com.au (historical) | Source list; Simply Wall St |
| Website (current operator) | jayex.com (© 2026 Jayex Limited) | jayex.com |
Jayex is one of the longest-established suppliers of patient-flow technology to UK primary care. Its products cover self check-in kiosks, patient calling displays and waiting-room management. They are sold mainly to NHS GP practices, Primary Care Networks and community trusts on recurring licence-plus-hardware contracts. The listed Australian parent, Jayex Healthcare/Jayex Technology Limited, was assembled in 2015 around the UK business and an Australian appointments app (Appointuit). It later tried adjacent bets, including remote pharmacy dispensing (BluePoint) and a New Zealand medicinal cannabis licence (Whakaora Hou). None reached scale.
Revenue never exceeded about A$7.2m. The group was persistently loss-making and relied on related-party funding from its chairman's interests. It exited acute hospital queue management in 2021, and its UK operating company entered administration in August 2024. The franchise survives commercially under private owner Jayex Limited, which claims more than 1,800 UK practices on active subscriptions. For the listed company's equity holders, the investment case has effectively ended.
Company's own description (paraphrased)
In its 2020 annual report and its 2021–2022 filings, the company described its principal activities as follows (paraphrased):
-
providing service technologies to the healthcare industry; and
-
developing integrated dispensing automation systems for the pharmaceutical and healthcare sectors.
After the 2021 divestment of the acute hospital business, the 1H FY2022 report narrowed this focus. Growth would come from UK primary care and NHS community markets through the company's SaaS-based Jayex Connect platform, supported by continued product innovation.
Market Index's company profile (drawn from company materials) describes a business evolving to support how patients now want to engage with their GP. That includes social prescribing and care navigation alternatives across primary care.
Independent characterisation
Jayex is best understood as a niche, hardware-enabled vertical SaaS vendor in UK primary-care front-office workflow. Its core value proposition is threefold:
-
Patient arrival (self check-in): A touchscreen kiosk (floor, wall or desk mounted) or mobile check-in via SMS link or QR code. It verifies the appointment against the practice's clinical system and marks the patient as arrived. It can also capture or update demographic data such as mobile number and email.
-
Patient calling: Screens in the waiting room call patients to clinicians. They show the patient's name or a ticket number, which supports privacy and GDPR compliance, and display health messaging between calls.
-
Waiting-room visibility and engagement: A live dashboard of waiting patients (branded QView under Jayex Limited), plus surveys, campaigns, an information hub and reporting.
The key technical moat is integration with the UK GP clinical systems: EMIS Web (now Optum), Vision (INPS, now Cegedim) and TPP SystmOne. Each integration requires accreditation and partner status. Jayex was listed as a partner in the EMIS and Vision partner directories, and NHS Digital certified its Enlighten E4 product with TPP SystmOne appointments. Health Tech Newspaper (htn.co.uk) reported that Jayex was at that time the only provider integrated with all three systems for both patient calling and self-arrivals.
Revenue model
| Revenue stream (AUD) | 1H2021 | 1H2022 |
|---|---|---|
| Supply and installation of kiosks (point in time) | 769,706 | 1,152,038 |
| Software licences and support services (over time) | 923,509 | 1,119,133 |
| Extended warranty (over time) | 132,819 | 248,625 |
| Software development support services (over time) | 4,730 | 0 |
| Total revenue from continuing operations | 1,830,764 | 2,519,796 |
The group's revenue in the last period disclosed by product line (1H FY2022) split into four streams:
Source: 1H FY2022 Appendix 4D, Note 5: Recurring streams (licences and support, extended warranty) were about 54% of 1H FY2022 revenue (derived). Hardware supply and installation made up about 46% (derived). This mix shows a hybrid model: kiosk and screen hardware is sold or installed up front, and multi-year software licences and support produce annuity revenue.
Contract liabilities (deferred revenue) were A$1.44m at 30 June 2022, which confirms that customers are invoiced in advance for licences and warranties. Q3 FY2022 commentary reported 883 annual licences billed, up from 776 in Q3 2021 (Stockhead quarterly round-up).
Value chain position
Jayex designs the software and integration layer and sources commercial-grade touchscreens and displays (anti-microbial coated screens are mentioned in partner materials). It also installs, maintains and supports the systems. Jayex Limited emphasises on-site engineer swap-out for failed hardware. It also runs its clinical-system integration on a dedicated Jayex-supplied PC inside the practice network, so that clinical data does not leave the practice.
Jayex sits downstream of the clinical-system vendors (EMIS, TPP, Cegedim/Vision), on whom it depends for API access and accreditation. It sits upstream of practices, PCNs, federations and NHS trusts, which buy directly or through NHS frameworks.
Customer types and end-markets
| End-market | Customer types | Status |
|---|---|---|
| UK primary care | GP practices, PCNs, GP federations, practice groups (e.g., Operose Health, Howbeck Healthcare, Sunderland GP Alliance named on jayex.com) | Core; continued under Jayex Limited |
| UK community and acute | NHS community trusts (e.g., Hertfordshire Community NHS Trust), hospital outpatient departments | Community continued; on-premises acute queue management sold to VitalHub in May 2021 |
| Australia and New Zealand primary care | GP clinics (integration with MedicalDirector Pracsoft), Appointuit app users | Scaled back in 2022; sales and product roles moved to the UK |
| Australian acute | Local Health Districts (e.g., North Sydney LHD QMS with Cerner) | Sold to VitalHub in 2021 |
| Pharmacy / dispensing | BluePoint remote dispensing terminals; 2018 licence to Medicann NZ | Dormant / not material |
| Medicinal cannabis (NZ) | Whakaora Hou Limited cultivation licence | Sale to Bioarc fell through in 2022; not commercialised |
Strategy
Stated strategy themes (latest filings accessed, paraphrased)
From the 1H FY2022 Directors' Report:
-
Focus: UK primary care and NHS community markets through the SaaS Connect platform, after exiting acute.
-
Innovation-led growth: Rollout of new products, including the Connect Information Kiosk and a Survey module.
-
Cost restructuring: Streamlined ANZ operations, with roles moved to the UK.
-
Balance sheet support: Ongoing related-party funding, with the Covenant note extended to 13 October 2023 and expected to be settled in equity.
-
Opportunistic adjacencies: Remote patient monitoring ("home care") was flagged in FY2020. Partnership-led expansion in New Zealand was mentioned in the FY2020 report (counterparty not identified in the excerpt accessed).
Market Index's company profile adds social prescribing and care navigation alternatives across primary care as strategic directions.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
The listed entity has made no strategic announcements since its June 2024 quarterly report (lodged 5 August 2024). Under Jayex Limited, the operating business has:
-
renewed ISO/IEC 27001:2022 certification (issued 16 January 2026) and certified to Cyber Essentials Plus (18 December 2025);
-
launched or rebranded QView waiting-room management and repositioned the website around GP practices, PCNs and hospitals;
-
published customer metrics: 1,800+ UK practices on active subscriptions, 98%+ annual retention (derived from monthly recurring revenue churn, 2025–26), a 4.7/5 support rating and 62% likelihood-to-recommend scores of 4–5 out of 5 (May 2026 survey, n=183).
ESG and cost programmes
No formal ESG commitments, emissions targets or quantified cost programmes were disclosed by the listed entity.
Medium-term targets and guidance
None were disclosed. The 1H FY2022 impairment testing used a one-year management forecast of year-on-year revenue growth from FY2023 onwards. Actual FY2023 revenue declined about 19%.
Products & Services
Primary care — Patient engagement (UK segment; now Jayex Limited)
| Product | Description and capabilities | Target customer | Launch / latest | Pricing |
|---|---|---|---|---|
| Jayex Connect platform | Cloud-based patient engagement platform combining check-in, calling, messaging, surveys and reporting. Needs no Microsoft updates on practice machines. Offers enterprise licensing and central reporting for PCNs and federations. | GP practices, PCNs, federations | Platform converged 2018; continuously updated | Annual licence plus hardware; enterprise licensing for groups. Specific prices not publicly disclosed. |
| Patient Check-in (kiosk) | Commercial-grade touchscreen kiosk (floor, wall or desk), height and wheelchair accessible, anti-microbial coating. Content in 45–48+ languages. Integrated arrival into EMIS, Vision or SystmOne. Up to 11 demographic fields can be reviewed or captured. | GP practices, community clinics | First kiosk developed 2004; current versions are Connect modules | Hardware supply and installation plus licence |
| Patient Mobile Check-in | Check-in through an SMS link or a practice-specific QR code. | GP practices | Connect-era module | Add-on |
| Patient Calling | Waiting-room displays calling patients by name or number, with health messaging. Descended from the D300 display. | GP practices, clinics, hospitals | D300 from 1996; Connect calling current | Hardware plus licence |
| QView waiting-room management | Live list of waiting patients by name or number, showing wait times and clinician, with "running late" flags. | Reception teams | Branded under Jayex Limited (2025–26 website) | — |
| Waiting-room media and screens | Digital signage with practice and health content. | GP practices | Current | — |
| Patient Communications / Surveys | Survey creation, SMS or email patient contact, check-in and check-out surveys, campaigns. A "Survey" innovation was cited as ready for rollout in 1H FY2022. | GP practices, PCNs | 2,022 | Add-on |
| Patient Information Hub | Health and practice information delivered at check-in, aimed at reducing digital health inequalities. | GP practices | Connect-era | Add-on |
| Connect Information Kiosk | Clinic kiosk for rebooking appointments, completing surveys and searching clinic online resources. | GP practices | Development completed 1H FY2022 | — |
| Enlighten (E4) | Earlier web-based waiting-room management for multi-practice sites, acute trusts, LIFT buildings and polyclinics. NHS Digital certified pairing with TPP SystmOne appointments. Trial data: 548 check-ins flagged 62 missing or incorrect mobile numbers and 78 emails. | Multi-practice sites, health centres | Pre-Connect generation | Legacy |
| X-Touch | Self check-in software pre-installed on touchscreens, communicating with InPS Vision 3.0. Developed with InPS. | Vision practices | Launched March 2005 | Legacy |
| D300 Patient Calling Display | Classic patient-calling LED or LCD display. | GP practices | 1,996 | Legacy |
Acute / hospital (divested May 2021)
| Product | Description | Customer | Status |
|---|---|---|---|
| QMS (Queue Management System) | On-premises hospital queue management with HL7 integration, deployed with Cerner at North Sydney LHD. | NHS trusts; Australian LHDs | Hospital contracts in the UK and Australia sold to VitalHub (TSXV: VHI) on 17 May 2021 |
Australia / New Zealand
| Product | Description | Customer | Status |
|---|---|---|---|
| Appointuit | Online appointment booking and patient engagement app, launched in 2011 and once Australia's most popular medical appointment app on the App Store and Google Play (Pulse+IT, 2015). | Australian GP clinics and patients | Founders exited in 2017; later status not disclosed |
| Jayex kiosks for Pracsoft | Self check-in integrated with MedicalDirector Pracsoft (from version 3.15.3a). Marks patients as "Waiting" in the Pracsoft waiting room. | Australian GP clinics | Australian operations scaled back in 2022 |
Pharmacy and dispensing automation
| Product | Description | Customer | Status |
|---|---|---|---|
| BluePoint | Remote pharmacy prescription processing and dispensing terminal, with kiosks. Licensed to Medicann NZ in July 2018 for a minimum of A$500k. | Pharmacies; cannabis dispensaries | No later commercial disclosures; dormant |
| Pharmacy Delivery | Listed by Market Index as one of four proprietary technologies (with Enlighten, Appointuit and BluePoint). | Pharmacies | — |
Other ventures
| Asset | Description | Status |
|---|---|---|
| Whakaora Hou Limited | NZ subsidiary holding a cannabis cultivation licence. | Bioarc withdrew its purchase offer in 1H 2022, citing poor NZ cannabis market conditions |
| Remote patient monitoring / home care | Explored as a growth segment in the FY2020 annual report. | No product disclosed |
Financial Narrative
Sources by year:
-
FY2019: FY2020 Annual Report comparatives.
-
FY2020 and FY2021: FY2021 Appendix 4E (FY2020 restated for discontinued operations).
-
FY2022 and FY2023: Morningstar data via Market Index. Audited full-year statements for these years were not directly accessed, so they are aggregator figures.
All figures are in A$ thousands unless stated.
Income statement
Notes:
-
FY2020 EBITDA (derived) includes a A$246k derivative fair-value gain and a A$106k foreign exchange gain.
-
FY2021 EBITDA (derived) includes the A$2,514k impairment and a A$1,038k derivative fair-value gain.
-
FY2023 D&A is reported as nil by Morningstar, consistent with intangibles having been fully written down by 31 December 2022.
-
Simply Wall St reports FY2023 revenue as A$3.8m (likely including other income), cost of revenue A$4.1m and gross profit of –A$330k. This is a different classification from the "revenue less raw materials" proxy above.
Margins and growth
FY2020 growth is measured against FY2019 on the originally reported basis (6,063 vs 7,185). The FY2021 growth rate uses the restated FY2020 continuing revenue. Morningstar's "NPAT margin" (–53.1% FY2022, –69.8% FY2023) is calculated on NPAT before abnormals.
Revenue CAGR (derived):
-
FY2020–FY2023 on the restated continuing basis (5,069 → 3,480): –11.8% a year.
-
FY2019–FY2023 on a mixed basis (7,185 → 3,480): –16.6% a year. This is not like-for-like because FY2019 includes the later-divested acute business.
Balance sheet
Notes:
-
FY2021 figures are as originally reported. After restatement, total assets were A$9,691k, intangibles A$5,177k and equity A$1,178k.
-
FY2022 and FY2023 net debt is calculated on short-term debt only (long-term debt was not available).
-
Equity was a deficiency at 31 December 2022 and 2023. Morningstar book value per share of about –A$0.02 implies roughly –A$5.6m (–0.02 × 281.28m shares, indicative only). Total assets of A$0.50m against current liabilities of A$6.53m at 31 December 2023 confirms a deficiency of at least A$6.0m.
-
The group had already reported a net liability position of –A$90k at 30 June 2022.
Cash flow
Half-year cash flow (1H FY2022): operating cash flow –A$204k; capex A$23k; repayment of borrowings A$176k; closing cash A$448k (1H FY2022 4D).
Ratios
Notes:
-
ROE and ROA for FY2020–21 are derived using average equity and assets where available.
-
FY2022–23 ROA, current ratio, quick ratio, asset turnover and inventory turnover are from Morningstar.
-
ROE is not meaningful for FY2022–23 because equity was negative. Morningstar shows positive ROE of about 36% for those years, which is an artefact of dividing a loss by negative equity.
-
Net debt/EBITDA is not meaningful because EBITDA was negative in most years.
-
ROIC and the cash conversion cycle could not be computed reliably from the disclosures accessed.
Commentary on trends, inflections and drivers
Revenue. The group peaked at A$7.2m in FY2019 (including acute). After that, three forces worked against it:
-
COVID-19 kept patients away from GP waiting rooms through 2020–21, which collapsed demand for check-in kiosks. Remote triage and telephone consultations replaced face-to-face arrival.
-
The May 2021 divestment of the acute QMS business removed about A$0.4m of revenue a half-year.
-
Australian and New Zealand revenue was deliberately scaled back from 2022.
FY2022 recovered 19.9% to A$4.3m as UK practices reopened and an "in-fill" order for kiosks arrived. The recovery stalled in FY2023 (–19.1% to A$3.48m). Management attributed the slowdown to NHS technology spending being paused while Clinical Commissioning Groups were reorganised into Integrated Care Boards (ICBs went live on 1 July 2022).
Profitability. The business was loss-making at the net level in every year examined. The gross-margin proxy is high (78–84%), but operating costs were about A$5–6m against revenue of A$3.5–5m, because the cost base was built for a larger company. Losses also carried heavy non-cash charges:
FY2021: goodwill and intangible impairment of A$2.5m.
FY2022: abnormals of A$3.75m, consistent with writing off the remaining A$3.45m of UK goodwill and other intangibles. Intangibles fell to nil by 31 December 2022.
FY2023: abnormals of A$1.5m, consistent with writing off the A$1.4m Brainworks investment. Non-current investments fell to nil.
Underlying EBITDA swung from roughly breakeven in FY2020 to –A$2.4m in FY2023, a clear deterioration in the core business.
Balance sheet. Total assets shrank from A$12.4m to A$0.5m in four years as goodwill, intangibles and investments were written off. The group was funded by:
-
related-party convertible notes and loans (Covenant Holdings (WA), linked to chairman Michael Boyd);
-
two £600k NatWest loans at 2.05% (repayable by June 2026 and February 2027);
-
small equity raisings (A$0.7m in FY2020; A$1.3m in FY2021, including the September 2021 rights issue at A$0.025).
The auditor flagged a material uncertainty about going concern in the 1H FY2022 review report. By 31 December 2023 the current ratio had fallen to 0.08x and cash to A$50k. The UK administration in August 2024 followed from this.
Cash flow. Operating cash burn widened from –A$0.18m (FY2020) to –A$1.26m (FY2021). Capex was minimal (A$0.1–0.3m), so R&D was evidently not capitalised at scale. Free cash flow was negative in every year accessible.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment (AUD) and Revenue by Segment (%)
| Segment metric (AUD) | 1H2021 | 1H2022 |
|---|---|---|
Australia revenue | 325,464 | 190,864 |
United Kingdom revenue | 1,505,300 | 2,328,932 |
Total revenue | 1,830,764 | 2,519,796 |
Australia EBITDA | -444,487 | -433,687 |
United Kingdom EBITDA | 513,331 | 32,347 |
Group segment EBITDA | 68,844 | -401,340 |
Australia share of revenue (%) | 17.8 | 7.6 |
United Kingdom share of revenue (%) | 82.2 | 92.4 |
Segment Assets & Liabilities (AUD)
| Segment balance sheet (AUD) | Dec2021 | Jun2022 |
|---|---|---|
Australia total assets | 2,909,954 | 2,622,839 |
United Kingdom total assets | 6,781,545 | 5,796,466 |
Australia total liabilities | 3,538,098 | 3,868,758 |
United Kingdom total liabilities | 4,975,778 | 4,640,665 |
Group Entities
| Entity | Jurisdiction | Role | Status |
|---|---|---|---|
Jayex Technology Limited (formerly Jayex Healthcare Limited) | Australia | ASX-listed parent | Suspended |
Jayex Technology Limited (UK) | England & Wales | Main operating company (UK CGU) | Administration from Aug 2024; business sold |
Australian operating entity / Appointuit | Australia | AU primary care; app | Scaled back 2022 |
Whakaora Hou Limited | New Zealand | Holder of NZ cannabis cultivation licence | Held; sale to Bioarc withdrawn 2022 |
Jayex Limited (not a group entity) | UK | Current owner of the Jayex business | Private; acquired the business in 2024 |
Income Statement and Per-Share Data
| Metric (AUD K) | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Revenue, as originally reported | 7,185 | 6,063 | 3,586 | 4,300 | 3,480 |
Revenue, continuing operations (restated basis) | — | 5,069 | 3,586 | 4,300 | 3,480 |
Other income | — | 545 | 251 | 190 | 330 |
Raw materials and consumables | — | 1,091 | 571 | — | — |
Revenue less raw materials (derived gross profit proxy) | — | 3,978 | 3,015 | — | — |
Employee benefits expense | — | 3,151 | 3,048 | — | — |
Depreciation and amortisation | — | 854 | 606 | 630 | 0 |
Impairment of intangibles / abnormals | — | 0 | 2,514 | 3,750 | 1,500 |
EBITDA (derived FY2020–21; Morningstar FY2022–23) | — | 136 | -2,753 | -820 | -2,420 |
Underlying EBITDA excl. impairment and derivative fair-value gains (derived) | — | -110 | -1,277 | -820 | -2,420 |
EBIT / operating income (derived FY2020–21; Morningstar FY2022–23) | — | -718 | -3,359 | -1,450 | -2,420 |
Finance costs | — | 380 | 841 | 930 | 170 |
Pre-tax income, continuing (FY2022–23 pre-abnormals) | — | -1,098 | -4,200 | -2,370 | -2,590 |
Net income attributable to owners | -960 | -799 | -3,724 | -7,250 | -3,930 |
EPS basic (A$ cents) | — | -0.4 | -1.7 | -2.9 | -1.45 |
EPS diluted (A$ cents) | — | -0.4 | -1.7 | -2.9 | -1.45 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Revenue growth YoY (restated basis) | — | -15.6 | -29.3 | 19.9 | -19.1 |
Gross margin proxy (revenue less raw materials) | — | 78.5 | 84.1 | — | — |
EBITDA margin | — | 2.7 | -76.8 | -19.1 | -69.5 |
Underlying EBITDA margin | — | -2.2 | -35.6 | -19.1 | -69.5 |
Operating (EBIT) margin | — | -14.2 | -93.7 | -33.7 | -69.5 |
Net margin (reported NPAT / revenue) | -13.4 | -15.8 | -103.8 | -168.6 | -112.9 |
Balance Sheet
| Metric (AUD K, at 31 December) | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Total assets | — | 12,359 | 10,077 | 2,310 | 500 |
Cash and equivalents | 281 | 1,182 | 983 | 240 | 50 |
Short-term borrowings | — | 2,961 | 2,607 | 6,150 | 2,760 |
Long-term borrowings | — | 1,716 | 2,455 | — | — |
Total borrowings | — | 4,677 | 5,062 | — | — |
Net debt (derived) | — | 3,495 | 4,079 | 5,910 | 2,710 |
Total equity | 4,161 | 3,377 | 1,483 | — | — |
Goodwill and intangibles | — | 9,237 | 5,545 | 0 | 0 |
Total current assets | — | 2,752 | 2,117 | 810 | 500 |
Total current liabilities | — | 6,761 | 5,870 | 10,750 | 6,530 |
Working capital (derived) | — | -4,009 | -3,753 | -9,940 | -6,030 |
Contract liabilities (deferred revenue) | — | 1,436 | 1,615 | — | — |
Issued capital | 26,166 | 26,861 | 28,112 | — | — |
Accumulated losses | -20,557 | -21,356 | -25,080 | — | — |
Cash Flow
| Metric (AUD K) | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Operating cash flow | — | -183 | -1,257 | — | — |
Capex (PP&E plus intangibles) | — | 271 | 135 | — | — |
Free cash flow (derived) | — | -454 | -1,392 | — | — |
Proceeds from share issues (gross) | — | 700 | 1,292 | — | — |
Proceeds from borrowings | — | 1,060 | 1,116 | — | — |
Proceeds from disposal of acute business | — | 0 | 1,584 | — | — |
Payment for investments (Brainworks) | — | 0 | 1,369 | — | — |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
ROE (%) | -21.2 | -153.3 | — | — |
ROA (%) | — | -33.2 | -71.0 | -458.9 |
Current ratio (x) | 0.41 | 0.36 | 0.07 | 0.08 |
Quick ratio (x) | — | — | 0.06 | 0.05 |
Debt / equity (x) | 1.38 | 3.41 | — | — |
Interest coverage, EBIT / finance costs (x) | -1.9 | -4.0 | -1.6 | -14.2 |
Asset turnover (x) | 0.41 | 0.32 | 1.86 | 6.91 |
Inventory turnover (x) | — | — | 30.89 | 20.65 |
Region revenue (AUD)
| Region revenue (AUD) | 1H2021 | 1H2022 |
|---|---|---|
United Kingdom | 1,505,300 | 2,328,932 |
Australia (including NZ) | 325,464 | 190,864 |
Total | 1,830,764 | 2,519,796 |
Region growth and share (%)
| Region growth and share (%) | 1H2021 | 1H2022 |
|---|---|---|
United Kingdom growth YoY | — | 54.7 |
Australia growth YoY | — | -41.4 |
United Kingdom share of total | 82.2 | 92.4 |
Australia share of total | 17.8 | 7.6 |
UK CGU revenue (GBP)
| UK CGU revenue (GBP) | FY2021 |
|---|---|
UK CGU revenue used for impairment testing | 2,512,537 |
Per-Share Data and Share Count (millions)
| Metric (A$ per share) | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
June share price close | 0.145 | 0.023 | 0.025 | 0.048 | 0.018 | 0.026 | 0.005 | 0.009 | 0.001 |
Metric (AUD Mn, 31 December) | FY2022 | FY2023 | — | — | — | — | — | — | — |
Market capitalisation | 3.09 | 2.53 | — | — | — | — | — | — | — |
Enterprise value | 10.96 | 6.06 | — | — | — | — | — | — | — |
Shares outstanding (millions) | 281.28 | 281.28 | — | — | — | — | — | — | — |
Share Price & Returns
| Period | Return (%) |
|---|---|
1-year (Jun 2023 to Jul 2024) | -88.9 |
3-year (Jun 2021 to Jul 2024) | -96.2 |
5-year (Jun 2019 to Jul 2024) | -97.9 |
Since listing year (Jun 2016 to Jul 2024) | -99.3 |
Valuation Multiples
| Multiple (x) | FY2022 | FY2023 |
|---|---|---|
P/E | -1.20 | -1.00 |
Price / book | -0.49 | -0.37 |
Price / cash flow | -8.03 | -1.50 |
EV / sales (derived: EV ÷ trading revenue) | 2.55 | 1.74 |
Capital Instruments
| Instrument | Face / carrying | Rate | Maturity | Outcome |
|---|---|---|---|---|
Covenant convertible notes | Face A$2.7m (carrying A$2.52m) | 6.5% | 13 Oct 2022, extended to 13 Oct 2023 | Converted Mar 2023 (250m securities at A$0.015) |
Related-party loan (Covenant) | A$0.74m | 0% (unsecured) | 1 Apr 2023 | — |
NatWest loan 1 | £600k original (£480k outstanding) | 2.05% | Jun 2026 | Obligation of the UK subsidiary; subject to the administration |
NatWest loan 2 | £600k original (£560k outstanding) | 2.05% | Feb 2027 | Same as above |
Lease liabilities | A$0.18m | — | Short-dated | — |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance
None. The listed entity has issued no guidance since its last periodic report (5 August 2024). Its last forward-looking statement (1H FY2022) expected improved UK trading and year-on-year revenue growth from FY2023. That did not happen: FY2023 revenue fell about 19%.
Consensus
No coverage exists, so there is no consensus.
Bull-case arguments (franchise-level; limited relevance to JTL equity)
-
The franchise survived insolvency intact. Jayex Limited kept the products, engineers and support team. It reports 1,800+ practices and 98%+ annual retention, showing the customer base is worth more than the listed group's capital structure implied.
-
Integration moats endure. Accredited integration with EMIS, Vision and SystmOne, plus dedicated in-practice hardware, creates high switching costs. The listed group's 84% gross-margin proxy (FY2021) suggests attractive unit economics once overhead is right-sized.
-
Recapitalised ownership can invest. Freed from A$5–6m of debt-like liabilities and listed-company costs, a private owner could pursue PCN enterprise licensing, survey modules and hardware refresh cycles that the listed group could not fund.
Bear-case arguments
-
JTL equity is likely worthless. The listed parent lost its main operating subsidiary to administration. It reported cash of A$50k and an equity deficiency of at least A$6m at 31 December 2023, and is likely to be removed from the ASX.
-
Structural demand erosion. Digital-first GP access and remote triage reduce waiting-room dependence, and revenue fell at an –11.8% CAGR from FY2020 to FY2023 on a like-for-like basis.
-
Platform-owner and scale risk. Clinical-system vendors and well-funded communications platforms (Accurx, iPlato) can bundle arrival and calling features. A sub-A$5m vendor has little R&D capacity to respond.
Catalysts and monitorables (next 12 months)
-
ASX confirmation of removal of JTL from the official list (expected around August 2026; verify).
-
FRP Advisory administrators' progress reports (Companies House): sale consideration and returns to creditors, including any intercompany claim by the Australian parent.
-
Any liquidation or deregistration of the Australian parent and its NZ subsidiary (Whakaora Hou).
-
Jayex Limited customer metrics, accreditation renewals (ISO 27001 expires 25 January 2027; Cyber Essentials Plus expires 18 December 2026) and any NHS framework awards.
-
NHS policy on GP digital front-door funding, and native features from EMIS/Optum and TPP.
Concluding analyst verdict
Jayex Healthcare Limited, renamed Jayex Technology Limited in May 2021, is a cautionary case of a sound niche franchise held inside an unsustainable listed structure. The underlying asset was a 1978-vintage UK patient-flow business. It had integrations with every major GP clinical system, an installed base in the low thousands of practices and a high gross margin. The 2015 listing bundled that asset with Australian adjacencies that never earned their keep, including Appointuit, BluePoint, a New Zealand cannabis licence and a later US$1m bet on Brainworks.
Revenue peaked at about A$7.2m in FY2019. COVID-19 then emptied GP waiting rooms, the acute business was sold to VitalHub in 2021, and NHS spending paused during the 2022 ICB reorganisation. By FY2023, revenue of A$3.48m supported a cost base that produced an EBITDA loss of about A$2.4m. Cumulative net losses from FY2019 to FY2023 were about A$16.7m, and goodwill and investments of more than A$10m were written off.
Throughout, the group survived on related-party funding from its chairman's interests. That created heavy governance concentration and left minority holders highly diluted. The end came in 2024: repeated ASX suspensions, then the UK operating company's administration in August. The business was sold to private buyer Jayex Limited.
For holders of JTL shares, our assessment is that recoverable value is negligible to nil, and the security should be treated as a write-off pending formal ASX removal. Any residual value would depend on administrators' distributions or intercompany claims, which appear unlikely. For strategic observers, the Jayex franchise looks healthy under private ownership: 1,800+ practices, 98%+ retention and renewed ISO 27001 and Cyber Essentials Plus accreditation. It remains a credible acquisition target or partner for a larger UK primary-care software group.
Verdict: JTL equity is uninvestable. The Jayex franchise (Jayex Limited) is a niche asset worth monitoring as private-market or M&A intelligence.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / dates | Background (as disclosed) | Holdings (latest notice) |
|---|---|---|---|---|
Michael Denis Boyd (B.Com) | Chairman (Executive Chairman in 2022 filings; recorded as Non-Executive Chairman from Oct 2022) | Director since listing (2015); moved to a non-executive role in Jun 2017; signed the 2022 reports as Chairman | Over 27 years founding enterprises in healthcare, telecoms and finance. Founded Foundation Healthcare, which grew to more than 800 healthcare professionals before being acquired by Sonic Healthcare; described by Pulse+IT as a Sonic Healthcare co-founder. Founding partner of Iridium Satellite during its emergence from bankruptcy. | Indirect 110,883,880 shares; 250,000,000 options/convertibles (notice 2 May 2024) |
Brian Renwick | Non-Executive Director | Director through the 2021–2024 filings; consultant to Jayex since 2006 | Pharmaceutical manufacturing and supply-chain roles, then wholesale business development in retail and hospital pharmacy. General manager of a corporate pharmacy business; two business development roles within the CSL Limited group. | 1,660,871 shares (notice 2 May 2024) |
Michael Chan | Non-Executive Director | — | — | Previously 624,545 shares from the 2021 rights issue plus on-market purchases |
Nicholas Harper | Executive Director | — | Senior UK operational role implied (Executive Director); details not disclosed | — |
William Denis Boyd | Non-Executive Director | Appointed June 2024 | — | 0 shares (notice 4 Jun 2024) |
“—” = not publicly disclosed.
Governance Detail
| Role | Name | Notes |
|---|---|---|
CEO / Managing Director | Not publicly disclosed in documents accessed | The Executive Chairman (Michael Boyd) and Executive Director (Nicholas Harper) appear to have performed executive functions in 2022 |
CFO / Company Secretary | Not publicly disclosed in documents accessed | — |
Jayex Limited (current operator) leadership | Not publicly disclosed on jayex.com | — |
Board & Management Changes
| Date | Change |
|---|---|
Jun 2017 | Michael Boyd moves to a non-executive role (Pulse+IT) |
| 2022 | Board comprises Boyd (Executive Chairman), Renwick, Chan and Harper |
Oct 2022 | Boyd recorded as Non-Executive Chairman (Market Index) |
Jun 2024 | William Denis Boyd appointed Non-Executive Director |
Major Shareholders
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | Lirho Pty Ltd <Boyd 4 A/C> | 103,883,880 | 36.93 |
| 2 | Vector London Ltd | 19,003,378 | 6.76 |
| 3 | Mary Kathleen Simcox | 17,500,000 | 6.22 |
| 4 | Donovan Products Pty Ltd <Family A/C> | 12,035,943 | 4.28 |
| 5 | Turbine Capital Limited | 8,800,000 | 3.13 |
| 6 | Covenant Holding (WA) Pty Ltd | 7,000,000 | 2.49 |
| 7 | Citicorp Nominees Pty Limited | 6,455,163 | 2.29 |
| 8 | BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient> | 5,990,327 | 2.13 |
| 9 | Mr Joel David Webb | 5,500,000 | 1.96 |
| 10 | Mrs Vanessa Faye Connor | 5,174,808 | 1.84 |
Competitive Landscape
Key Competitors
| Competitor | HQ | Segment overlap | Relative positioning vs Jayex |
|---|---|---|---|
Qmatic | Sweden | Queue management and customer flow, including healthcare | Global scale; strong in hospitals and public sector; less GP-system integration depth |
Wavetec | UAE / UK | Queue management kiosks and displays | Generalist queue management; competes on hardware |
Q-nomy | Israel | Queue and appointment management for healthcare and government | Enterprise focus |
VitalHub Corp (TSXV: VHI) | Canada | Patient flow and queue management in the UK acute market (owns Jayex's former acute QMS contracts) | Larger, acquisitive; now the acute incumbent where Jayex exited |
Accurx | UK | GP patient messaging, online consultation, booking | Dominant in UK GP digital communications; adjacent rather than kiosk-based |
iPlato (myGP) | UK | Patient messaging, app, booking | Adjacent; patient engagement via mobile |
EMIS / Optum Patient Access | UK | Patient app, online booking, arrivals features in the clinical system | Platform owner and partner; risk of native features displacing third parties |
TPP (SystmOne / Airmid) | UK | Clinical system with patient-facing features | Same platform-owner risk |
Envisage-type UK check-in kiosk vendors and local AV/IT integrators | UK | GP self check-in and calling screens | — |
HotDoc | Australia | GP booking, check-in, recalls | Dominant in Australian primary care booking; displaced Appointuit-type apps |
HealthEngine | Australia | Consumer appointment booking | Same as above |
Omnicell / BD Rowa | US / Germany | Pharmacy dispensing automation | Far larger; makes BluePoint uncompetitive |
Competitor Detail
| Metric | Jayex (FY2023) |
|---|---|
Revenue (AUD Mn) | 3.48 |
Revenue growth (%) | -19.1 |
EBITDA margin (%) | -69.5 |
Net margin (%) | -112.9 |
R&D intensity (capitalised development % revenue, FY2021) | 2.5 |
Listed | ASX (suspended) |
Recent Developments
The listed entity has published no identifiable announcements since August 2024, so the 18-month window holds few listed-company events.



